Fogarty’s Cleeland on impact of MedTech innovation; Soriano highlights Baxter’s hurricane response

In this week’s episode of the DeviceTalks Weekly Podcast, Andrew Cleeland, CEO of the Fogarty Institute, shares his MedTech story, starting with a serendipitous move into the industry. Cleeland, of course, went on to lead two successful startups from The Foundry - Ardian and Twelve, that both went on to be acquired by Medtronic. Cleeland now leads one of the industry’s most successful incubator programs, the Fogarty Institute.  Cleeland will share insights on leading a MedTech start-up and shares some concerns he has for the industry at large.

The Fogarty Institute is also promoting the Thomas J. Fogarty prize for medical innovation, a $100,000 prize for one person or a small group of people who have broken new ground in the industry. Go to this article at Medical Design & Outsourcing for more information.

https://www.medicaldesignandoutsourcing.com/mike-mussallem-tom-fogarty-prize-medtech-innovation/

Before that conversation, Host Tom Salemi and Holly Scott, managing partner at The Mullings Group, interviewed Cecilia Soriano, global president of Infusion Therapies and Technologies, at Baxter. We’ll preview Soriano’s interview at DeviceTalks Boston where she’ll talk about Baxter’s recovery from Hurricane Helene.

But we’ll start the episode off with MassDevice Editor Chris Newmarker’s Newmarker’s Newsmakers including the FDA, HHS, Alcon, Abbott and Johnson & Johnson MedTech.

Thanks for listening to this episode of the DeviceTalks Weekly podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.